Trials 22 · a red edge is where a trial was stopped
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCN-01 | “7-Hydroxystaurosporine (UCN-01) is a protein kinase inhibitor that inhibits several serine-threonine kinases including PKC and PDK1.” PMID 17429623 ↗ Apr 20076“UCN-01 (7-hydroxystaurosporine) is an investigational agent that exhibits antitumor activity by perturbing the cancer cell cycle.” PMID 20967484 ↗ Oct 2010 “This is a phase I study of 7-hydroxystaurosporine (UCN-01) and fludararbine monophosphate (FAMP) in relapsed lymphoma.” PMID 21745173 ↗ Jul 2011 “UCN-01 (7-hydroxy-staurosporine) is a novel antineoplastic agent targeting cyclin-dependent kinases” PMID 15958629 ↗ Jun 2005 “7-hydroxystaurosporine (UCN-01)” NCT00001444 ↗ “7-hydroxystaurosporine (UCN-01)” NCT00004263 ↗ |
| Known as | 7-hydroxystaurosporine | “This study will examine the effects of an experimental drug called UCN-01 (7-hydroxystaurosporine) on T-cell lymphomas.” NCT00082017 ↗22“UCN-01 (7-hydroxy-staurosporine) is a novel antineoplastic agent targeting cyclin-dependent kinases” PMID 15958629 ↗ Jun 2005 |
| Known as | KRX-0601 | ChEMBL registry synonym — accepted as the source's own label CHEMBL574737 ↗ |
| Known as | KW-2401 | ChEMBL registry synonym — accepted as the source's own label CHEMBL574737 ↗ |
| Known as | NSC-638850 | ChEMBL registry synonym — accepted as the source's own label CHEMBL574737 ↗ |
| Known as | UCN-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL574737 ↗ |
| Action | Inhibit | “3-phosphoinositide dependent protein kinase-1 inhibitor” CHEMBL574737 ↗5“Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL574737 ↗ “Cyclin-dependent kinase 6 inhibitor” CHEMBL574737 ↗ “Cyclin-dependent kinase 4 inhibitor” CHEMBL574737 ↗ “Cyclin-dependent kinase 2 inhibitor” CHEMBL574737 ↗ “a protein kinase C inhibitor” NCT00001444 ↗ |
| Modality | Small molecule | — CHEMBL574737 ↗ |
| Route | Intravenous | “72-hours intravenous continuous infusions” NCT00001444 ↗ |
| Target | ALK | “Anaplastic lymphoma receptor tyrosine kinase (ALK) is one potential target for UCN-01 action” NCT00082017 ↗ |
| Target | CDK2 | “Cyclin-dependent kinase 2 inhibitor” CHEMBL574737 ↗ |
| Target | CDK4 | “Cyclin-dependent kinase 4 inhibitor” CHEMBL574737 ↗ |
| Target | CDK6 | “Cyclin-dependent kinase 6 inhibitor” CHEMBL574737 ↗ |
| Target | CHEK1 | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL574737 ↗ |
| Target | PDPK1 | “3-phosphoinositide dependent protein kinase-1 inhibitor” CHEMBL574737 ↗ |